Vetigenics: Funding, Investors & Team (Aug 2026)
Vetigenics develops new immunotherapies for treating cancer and chronic conditions in dogs, which do not have harmful side effects. By using our fully canine phage display platform, we can quickly identify unique antibody fragments or CANIBODIES™ that can bind to any target antigen with high affinity and functionality. These CANIBODIES™ are created from canine genes without the need for expensive and time-consuming adaptations, and can easily be turned into various types of therapies. Our treatments are designed to be highly effective and non-immunogenic, a feat that is not possible with other methods. Vetigenics is currently moving three antibody products through development and plans to start clinical trials in dogs in the first quarter of 2021.
Vetigenics has raised $6.0M across 1 funding round on record, the most recent a Seed of $6.0M announced in Feb 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vetigenics Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Vetigenics Funding Rounds
Vetigenics Founders and Leadership Team
No contact details are on record for this team yet.
Vetigenics Funding Compared to Other Biotechnology Startups
Vetigenics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vetigenics in Biotechnology and Philadelphia
Companies Similar to Vetigenics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Vetigenics Funding FAQs
What does Vetigenics do?
Vetigenics develops new immunotherapies for treating cancer and chronic conditions in dogs, which do not have harmful side effects. By using our fully canine phage display platform, we can quickly identify unique antibody fragments or CANIBODIES™ that can bind to any target antigen with high affinity and functionality. These CANIBODIES™ are created from canine genes without the need for expensive and time-consuming adaptations, and can easily be turned into various types of therapies. Our treatments are designed to be highly effective and non-immunogenic, a feat that is not possible with other methods. Vetigenics is currently moving three antibody products through development and plans to start clinical trials in dogs in the first quarter of 2021.
How much funding has Vetigenics raised?
Vetigenics has raised $6.0M across 1 round on record. The most recent is a Seed of $6.0M announced in Feb 2025.
When did Vetigenics last raise funding?
Vetigenics' most recent funding round on record is a Seed of $6.0M, announced in Feb 2025.
Who founded Vetigenics?
FundedIQ lists Adriann Sax (Founder) at Vetigenics.
Where is Vetigenics headquartered?
Vetigenics is based in Philadelphia, Pennsylvania, United States.
How many employees does Vetigenics have?
Vetigenics is in the 1-10 employee band.
How does Vetigenics' funding compare to other Biotechnology startups?
Vetigenics' latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Vetigenics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vetigenics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.